# Rongcan Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rongcan-biotech

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.rc-rna.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 6, 2023)
- Investors on record: 5

## About

Established in 2020 and based in Wuhu, China, Rongcan Biotech operates as a nucleic acid drug developer, dedicated to the development and industrialization of gene drugs. The company's core technical members graduated from MIT and Harvard Medical School. It has established a joint laboratory of drug slow-release technology with Shanghai Jiao Tong University School of Pharmacy and has cooperated with WuXi AppTec Group and HuiGene Therapeutics. In December 2023, Rongcan Biotech raised more than CNY 100 million in series A funding.

Rongcan Biotech has established a nucleic acid drug RTP R&D technology platform to research and develop mRNA and SiRNA drugs. The company's product pipelines cover drugs in respiratory, cardiovascular, and solid tumors, as well as mRNA vaccines for infectious diseases.

## Funding rounds

- Series A, Dec 6, 2023, $14M — Yuexiu Industrial Investment Funds Management, Huafang Capital, Shanxi Growth Enterprise Leading Fund, King Tactics Capital
- Angel, Jun 24, 2020 — Spring Collection Assets Management

## Investors

- Spring Collection Assets Management (https://capitalatlas.ai/funds/spring-collection-assets-management) — Angel
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series A
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- Shanxi Growth Enterprise Leading Fund (https://capitalatlas.ai/funds/shanxi-growth-enterprise-leading-fund) — Series A
- King Tactics Capital — Series A